Cardiol Therapeutics (TSE:CRDL) Sets New 1-Year Low – Time to Sell?

Cardiol Therapeutics Inc. (TSE:CRDL) shares reached a new 52-week low during trading on Friday . The stock traded as low as C$1.69 and last traded at C$1.70, with a volume of 80251 shares trading hands. The stock had previously closed at C$1.75.

Cardiol Therapeutics Stock Down 1.7 %

The company has a debt-to-equity ratio of 1.59, a quick ratio of 6.84 and a current ratio of 2.49. The firm has a fifty day moving average price of C$1.91 and a 200 day moving average price of C$2.39. The firm has a market capitalization of C$142.72 million, a price-to-earnings ratio of -3.38 and a beta of 0.70.

Insider Activity

In other news, Director David Elsley acquired 40,000 shares of Cardiol Therapeutics stock in a transaction that occurred on Monday, December 16th. The stock was purchased at an average cost of C$1.88 per share, with a total value of C$75,072.00. Also, Senior Officer Guillermo Torre acquired 17,240 shares of Cardiol Therapeutics stock in a transaction that occurred on Thursday, December 26th. The shares were purchased at an average cost of C$1.81 per share, with a total value of C$31,277.77. Insiders acquired 86,140 shares of company stock valued at $161,456 in the last three months. 4.57% of the stock is currently owned by company insiders.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.